Literature DB >> 7603784

The nephropathy of type I tyrosinemia after liver transplantation.

J Laine1, M K Salo, L Krogerus, J Kärkkäinen, O Wahlroos, C Holmberg.   

Abstract

Type I tyrosinemia (HTI) is an autosomally recessively inherited disease caused by deficiency of fumarylacetoacetate hydrolase. The disease manifests with liver failure, renal tubular defects, and neurologic crises. Currently orthotopic liver transplantation (OLT) enables patients to survive. However, renal fumarylacetoacetate hydrolase deficiency is not corrected by OLT, and the long-term prognosis of the nephropathy is not known. We investigated tyrosine metabolism, GFR, renal tubular function, and histopathology before and 18-36 mo after OLT in eight patients with HTI. Progressive renal dysfunction was not documented despite continuing, although diminished, urinary succinylacetone excretion in all patients. The mean GFR was 82 mL/min/1.73 m2 before and 102 mL at 18 mo and 93 mL at 36 mo after OLT. All patients showed tubular dysfunction before OLT. At 18 mo, glucosuria occurred in one, amino aciduria and phosphaturia in three, and hypercalciuria in six patients. Only hypercalciuria was seen at 36 mo. Renal biopsies showed mild nonspecific changes caused either by minimal progression of the renal disease or by mild cyclosporine nephrotoxicity. In conclusion, patients with HTI had normal GFR, but showed signs of tubular dysfunction 18-36 mo after OLT. Renal function and histopathology should be monitored after OLT for HTI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603784     DOI: 10.1203/00006450-199505000-00015

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Increased excretion of coproporphyrin I in a patient with hereditary tyrosinaemia type I: relevant changes with NTBC treatment.

Authors:  C Depetris-Boldini; R Galetto; M P Videla; R de Kremer Dodelson
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

Authors:  L J W M Pierik; F J van Spronsen; C M A Bijleveld; C M L van Dael
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).

Authors:  E Pronicka; E Rowinska; Z Bentkowski; J Zawadzki; E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 4.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.

Authors:  David C Bartlett; Carla Lloyd; Patrick J McKiernan; Phil N Newsome
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

6.  Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Authors:  David C Bartlett; Mary Anne Preece; Elisabeth Holme; Carla Lloyd; Phil N Newsome; Patrick J McKiernan
Journal:  J Inherit Metab Dis       Date:  2012-03-29       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.